Intratumoral administration of the immunologic adjuvant AS01B in combination with autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma
===========================================================================================================================================================================================================================================

* Jens Tijtgat
* Xenia Geeraerts
* Anais Boisson
* Latoya Stevens
* Manon Vounckx
* Iris Dirven
* Julia Katharina Schwarze
* Steven Raeymaeckers
* Ramses Forsyth
* Ivan Van Riet
* Sandra Tuyaerts
* Karen Willard-Gallo
* Bart Neyns